Document:

Converted by EDGARwiz

  Exhibit 4.3 

SECOND AMENDED AND RESTATED VOTING AGREEMENT

This SECOND AMENDED AND RESTATED VOTING AGREEMENT (the “Agreement”) is made and entered into
effective as of October __, 2006, by and among Greenway Medical Technologies, Inc., a Georgia corporation (the “Company”), the holders of the Company’s Series A Preferred Stock (the “Series A
Preferred Stock”) listed on Schedule A hereto (collectively, the “Series A Investors”), the holders of the Company’s Series B Preferred Stock (the “Series B Preferred Stock”
and together with the Series A Preferred Stock, the “Preferred Stock”) listed on Schedule B hereto (collectively, the “Series B Investors”), and the holders of Common Stock of the Company
listed on Schedule C hereto (collectively, the “Common Holders”). The Company, the Series A Investors, the Common Holders and the Series B Investors are individually referred to herein as a
“Party” and are collectively referred to herein as the “Parties.” The Company’s Board of Directors is referred to herein as the “Board.”

WITNESSETH:

WHEREAS, the Company and the Series B Investors have entered into that certain Series B Preferred Stock Purchase Agreement of
even date herewith (the “Series B Purchase Agreement”), which provides for, among other things, the purchase by the Series B Investors of shares of the Series B Preferred Stock; 

WHEREAS, the Company’s Amended and Restated Articles of Incorporation (the “Articles of Incorporation”)
provide that (a) holders of shares of Common Stock, voting together as a class, shall elect two (2) members of the Board (the “Common Directors”), (b) holders of shares of the Series A Preferred Stock, voting together as
a class, shall elect two (2) members of the Board (the “Series A Directors”), (c) holders of shares of the Series B Preferred Stock, voting together as a class, shall elect one (1) member of the Board (the “Series B
Director”), and (d) the holders of shares of the Series A Preferred Stock, the holders of shares of Series B Preferred Stock and the holders of shares of Common Stock (voting together as a single class and not as separate series, and on
an as-converted basis) shall be entitled to elect the three (3) remaining members of the Board (“Industry Directors”); 

WHEREAS, to induce the Series B Investors to enter into the Series B Purchase Agreement and purchase shares of Series B Preferred
Stock thereunder, the Company, the Series A Investors and the Common Holders desire to amend and restate in its entirety that certain Interim Amended and Restated Voting Agreement dated as of September __, 2006 (the “Prior Agreement”)
to read as follows and enter into this Agreement with the Series B Investors;

WHEREAS, Section 16 of the Prior Agreement provides that the Prior Agreement may be amended only with the written consent of (i) the
Company, (ii) the holders of a majority of the then outstanding voting securities held by the Common Holders (as defined therein) and (iii) the holders of a majority of the then outstanding voting securities held by the Investors (as defined therein); and
 

WHEREAS, the parties to the Prior Agreement necessary to amend the Prior Agreement have resolved to do so, and such parties hereby
agree that this Agreement shall amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant hereto in lieu of the rights created under the Prior Agreement.

NOW, THEREFORE, in consideration of the foregoing premises and certain other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties agree as follows:

1.

Agreement to Vote. 

(a) Each Series B Investor, as a holder of Series B Preferred Stock, hereby agrees on behalf of itself and any transferee or assignee of
any such shares of Series B Preferred Stock, to hold all of the shares of Series B Preferred Stock registered in its name (and any securities of the Company issued with respect to, upon conversion of, or in exchange or substitution of such Series B Preferred
Stock, and any other voting securities of the Company subsequently acquired by such Series B Investor) (hereinafter collectively referred to as the “Series B Investor Shares”) subject to, and to vote the Series B Investor Shares at a
regular or special meeting of shareholders (or by written consent) in accordance with, the provisions of this Agreement. 

(b) Each Series A Investor, as a holder of Series A Preferred Stock, hereby agrees on behalf of itself and any transferee or assignee of any
such shares of Series A Preferred Stock, to hold all of the shares of Series A Preferred Stock registered in its name (and any securities of the Company issued with respect to, upon conversion of, or in exchange or substitution of such Series A Preferred
Stock, and any other voting securities of the Company subsequently acquired by such Series A Investor) (hereinafter collectively referred to as the “Series A Investor Shares”) subject to, and to vote the Series A Investor Shares at
a regular or special meeting of shareholders (or by written consent) in accordance with, the provisions of this Agreement. 

(c) Each Common Holder, as a holder of Common Stock of the Company, hereby agrees on behalf of itself and any transferee or assignee of any
such shares of Common Stock, to hold all of such shares of Common Stock and any other securities of the Company acquired by such Common Holder in the future (and any securities of the Company issued with respect to, upon conversion of, or in exchange or
substitution for such securities) (the “Common Holder Shares”) subject to, and to vote the Common Holder Shares at a regular or special meeting of shareholders (or by written consent) in accordance with, the provisions of this
Agreement.

2.

Board Size. The holders of Series B Investor Shares, the Series A Investor Shares and Common Holder Shares shall vote at a
regular or special meeting of shareholders (or by written consent) such shares that they own (or as to which they have voting power) to ensure that the size of the Board shall be set and remain at eight (8) directors; provided, however, that such
Board size may be subsequently increased or decreased pursuant to an amendment of this Agreement in accordance with Section 16 hereof.

3.

Election of Directors. 

(a) In any election of directors of the Company to elect the Common Directors, the Parties holding shares of Common Stock shall each vote
at any regular or special meeting of shareholders (or by written consent) such number of shares of Common Stock then owned by them (or as to which they then have voting power) as may be necessary to elect two (2) directors nominated by the holders of a
majority of the then outstanding shares of Common Stock, (i) one (1) of which directors shall be the Company’s chief executive officer, who shall be the Chairman of the Board, and (ii) one (1) of which directors shall be W.T. Green, III for so long
as he remains an officer of the Company, or, if W.T. Green, III no longer serves as an officer of the Company, such person as designated by W.T. Green, Jr.

- 2 -

(b) In any election of directors of the Company to elect the Series A Directors, the Parties holding shares of Series A Preferred Stock shall
each vote at any regular or special meeting of shareholders (or by written consent) such number of shares of Series A Preferred Stock then owned by them (or as to which they then have voting power) as may be necessary to elect two (2) directors nominated by
Investor Group, LP and Investor Growth Capital Limited (together, “IGC”), initially Noah Walley and Börje Ekholm, for so long as IGC collectively owns at least fifty percent (50%) of the Common Stock issued or issuable upon
conversion of the Series A Preferred Stock purchased by IGC pursuant to that certain Series A Purchase Agreement dated as of May 14, 2004 by and among the Company and the Series A Investors (as adjusted for stock splits, stock dividends, recapitalizations
or the like).

(c) In any election of directors of the Company to elect the Series B Director, the Parties holding shares of Series B Preferred Stock shall
each vote at any regular or special meeting of the shareholders (or by written consent) such number of shares of Series B Preferred Stock then owned by them (or as to which they then have voting power) as may be necessary to elect one (1) director nominated
by Wachovia Capital Partners 2006, LLC (“WCP”), initially D. Neal Morrison, for so long as WCP owns at least fifty percent (50%) of the Common Stock issued or issuable upon conversion of the Series B Preferred Stock purchased by WCP
pursuant to the Series B Purchase Agreement (as adjusted for stock splits, stock dividends, recapitalizations or the like).

(d) In any election of an Industry Director, the Series B Investors, the Series A Investors and the Common Holders shall each vote at any
regular or special meeting of shareholders (or by written consent) such number of voting securities of the Company then owned by them (or as to which they then have voting power) as may be necessary to elect (i) one (1) Industry Director that is nominated
by the Series A Directors and the Series B Director and approved by the Common Directors (with such approval not to be unreasonably withheld), (ii) one (1) Industry Director that is nominated by the Common Directors and approved by the Series A Directors
and the Series B Director (with such approval not to be unreasonably withheld) and (iii) one (1) Industry Director nominated by the Common Directors, the Series A Directors and the Series B Director. 

4.

Removal. Any director of the Company may be removed from the Board in the manner allowed by law and the Company’s Articles
of Incorporation and Bylaws, but with respect to a director designated pursuant to subsections 3(a), 3(b), 3(c) and 3(d) above, only upon the vote or written consent of the shareholders entitled to nominate such director.

5.

Bring Along Right. In the event that the Board and (X) the holders of a majority of the Series A Preferred Stock (voting
as a separate class) and (Y) the holders of a majority of the Series B Preferred Stock (voting as a separate class) (such holders of a majority of the Series A Preferred Stock and a majority of the Series B Preferred Stock collectively referred to as, the
“Required Holders”) approve either (i) an acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger or
consolidation) that would result in the transfer of fifty percent (50%) or more of the outstanding voting power of the Company or in which the shareholders of the Company immediately prior to such transaction would own, as a result of such transaction,
less than a majority of the voting securities, in the same relative proportions, of the successor or surviving corporation immediately thereafter or (ii) a sale of all or substantially all of the assets of the Company (such events described in
subsections (i) and (ii) are referred to herein as a “Sale of the Company”), then each Series B Investor, Series A Investor and Common Holder hereby agrees with respect to all securities of the Company which it own(s) or otherwise
exercises voting or dispositive authority:

- 3 -

(a) In the event such transaction is to be brought to a vote at a shareholder meeting, after receiving proper notice of any meeting of
shareholders of the Company to vote on the approval of a Sale of the Company, to be present, in person or by proxy, as a holder of shares of voting securities, at all such meetings and be counted for the purposes of determining the presence of a quorum
at such meetings;

(b) to vote (in person, by proxy or by action by written consent, as applicable) all shares of the capital stock of the Company as to which
it has beneficial ownership in favor of such Sale of the Company and in opposition of any and all other proposals that could reasonably be expected to delay or impair the ability of the Company to consummate such Sale of the Company;

(c) to refrain from exercising any dissenters’ rights or rights of appraisal under applicable law at any time with respect to such Sale
of the Company;

(d) to execute and deliver all related documentation and take such other action in support of the Sale of the Company as shall reasonably be
requested by the Company; 

(e) except for this Agreement, neither any of the parties hereto nor any affiliates thereof shall deposit any shares of capital stock
beneficially owned by such Party or affiliate in a voting trust or subject any such shares of capital stock to any arrangement or agreement with respect to the voting of such shares of capital stock; and

(f) Notwithstanding the foregoing, no Series B Investor, Series A Investor or Common Holder shall be required to vote in the manner
described by this Section 5 unless the net proceeds of such Sale of the Company are to be distributed to shareholders of the Company in accordance with the Company’s Articles of Incorporation, as amended.

In the event the Series A Investors and/or the Series B Investors exercise their redemption rights pursuant to the Amended and Restated Articles of Incorporation
of the Company and the Company fails to redeem any of the shares subject to redemption in accordance with the terms thereof by the Redemption Date (as defined in the Amended and Restated Articles of Incorporation), the Series A Investors or the Series
B Investors exercising their redemption rights shall have the right to elect to require a Sale of the Company. In connection therewith, they shall, to the extent practicable, engage on behalf of the Company one or more investment banking or brokerage
firms of national standing with experience in representing businesses engaged in the business of the Company to represent the Company and its shareholders in connection with the Sale of the Company. In the event of a Sale of the Company, all
shareholders shall receive the proceeds from such transaction pursuant to the provisions of Amended and Restated Articles of Incorporation of the Company notwithstanding the prior entitlement of any holders of Preferred Stock to have their Preferred
Stock redeemed pursuant to the Amended and Restated Articles of Incorporation. The investment banking firm shall be instructed to (i) prepare comprehensive marketing materials that communicate the key investment merits and focus potential purchasers
on additional value-creating opportunities, (ii) develop and implement an appropriate marketing strategy for the Sale of the Company (iii) identify all logical purchasers and contact key decision makers directly to ensure both confidentiality and a
quick response, (iv) to the extent possible, create a sense of urgency and competition among potential purchasers, and (v) solicit bona fide, written proposals or offers from prospective purchasers with respect to a transaction that results in the
Sale of the Company for cash and on such
other terms which the investment banking firm and outside legal counsel determine in good faith, and in the exercise of reasonable judgment, to be reasonably capable of being consummated (each a “Bona Fide Offer” and collectively,
the “Bona Fide Offers”). Promptly upon the investment banking firm’s receipt of Bona Fide Offers, the investment banking firm shall provide the Series A Investors, the Series B Investors and the Board with a written
summary containing all of the material terms of each Bona Fide Offer, including the present value of the aggregate cash consideration that the shareholders 

- 4 -

could reasonably expect to receive in each Bona Fide Offer. Unless otherwise agreed to by the Required Holders, the Bona Fide Offer that reflects the highest present value of the aggregate
cash consideration that the shareholders could reasonably expect to receive in each Bona Fide Offer (the “Superior Proposal”) shall be deemed accepted. Each Series B Investor, Series A Investor and Common Holder hereby agrees
with respect to all securities of the Company which it own(s) or otherwise exercises voting or dispositive authority (i) to take the actions set forth in clauses (a) – (d) of this Section 5 above to consummate the transactions contemplated by the
Superior Proposal and (ii) at the election of the Series A Investors or the Series B Investors exercising their redemption rights and notwithstanding the provision of Sections 2 or 3 of this Agreement, the Amended and Restated Articles of Incorporation
of the Company or otherwise to the contrary, to take all such actions requested by the Series A Investors or the Series B Investors exercising their redemption rights to cause the size of the Board to be set at three directors with (x) one director being
designated by the holders of a majority of the Common Stock and (y) two directors being designated by the Series A Investors and the Series B Investors exercising their redemption rights; provided, that, if the Series A Investors and the Series B Investors
exercise their redemption rights, the Series A Investors and the Series B Investors shall each (acting by a majority vote of such series) be entitled to elect one of such two directors.

6.

Legend on Share Certificates. Each certificate representing any Series B Investor Shares, Series A Investor Shares or Common
Holder Shares shall be endorsed by the Company with a legend reading substantially as follows:

“THE SHARES EVIDENCED HEREBY ARE SUBJECT TO AN AMENDED AND RESTATED VOTING AGREEMENT, AS AMENDED, (A COPY OF WHICH
MAY BE OBTAINED UPON WRITTEN REQUEST FROM THE ISSUER), AND BY ACCEPTING ANY INTEREST IN SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF SAID VOTING AGREEMENT.”

7.

Covenants of the Company. The Company will not, by any voluntary action, avoid or seek to avoid the observance or performance of
any of the terms to be performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all of the provisions of this Agreement and in the taking of all such actions as may be necessary, appropriate or reasonably requested
by the holders of a majority of the outstanding voting securities held by the Parties hereto (assuming conversion of all outstanding securities) in order to protect the rights of the Parties hereunder against impairment.

8.

No Liability for Election of Recommended Directors. Neither the Company, the Common Holders, the Series A Investors, the Series B
Investors, nor any officer, director, shareholder, partner, employee or agent of any such Party, makes any representation or warranty as to the fitness or competence of the nominee of any Party hereunder to serve on the Company’s Board by virtue of such
Party’s execution of this Agreement or by the act of such Party in voting for such nominee pursuant to this Agreement.

9.

Grant of Proxy. Upon the failure of any Party to vote their Series B Investor Shares, Series A Investor Shares or Common Holder
Shares, as applicable, in accordance with the terms of this Agreement, such Party hereby grants to a shareholder designated by the Board of Directors of the Company a proxy coupled with an interest in all Series B Investor Shares, Series A Investor Shares
and Common Holder Shares owned by such Party, which proxy shall be irrevocable until this Agreement terminates pursuant to its terms or this Section 9 is amended to remove such grant of proxy in accordance 

- 5 -

with Section 16 hereof, to vote all such Series B Investor Shares, Series A Investor Shares and Common Holder Shares in the manner provided in Sections 2 and
3 hereof.

10.

Specific Enforcement. It is agreed and understood that monetary damages would not adequately compensate an injured Party for the
breach of this Agreement by any other Party, that this Agreement shall be specifically enforceable, and that any breach or threatened breach of this Agreement shall be the proper subject of a temporary or permanent injunction or restraining order. Further,
each Party hereto waives any claim or defense that there is an adequate remedy at law for such breach or threatened breach.

11.

Execution by the Company. The Company, by its execution in the space provided below, agrees that it will cause the certificates issued
after the date hereof evidencing the shares of Series B Investor Shares, Series A Investor Shares and Common Holder Shares to bear the legend required by Section 6 hereof, and it shall supply, free of charge, a copy of this Agreement to any holder of a
certificate evidencing shares of capital stock of the Company upon written request from such holder to the Company at its principal office. The parties hereto do hereby agree that the failure to cause the certificates evidencing the shares of Series B
Investor Shares, Series A Investor Shares and Common Holder Shares to bear the legend required by Section 6 hereof and/or failure of the Company to supply, free of charge, a copy of this Agreement, as provided under this Section 11, shall not
affect the validity or enforcement of this Agreement.

12.

Captions. The captions, headings and arrangements used in this Agreement are for convenience only and do not in any way limit or
amplify the terms and provisions hereof.

13.

Notices. All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively given:
(i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after having
been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All
communications shall be sent to the respective parties at the addresses set forth on the signature pages attached hereto (or at such other addresses as shall be specified by notice given in accordance with this Section 13).

14.

Term. This Agreement shall terminate and be of no further force or effect upon (a) the consummation of the Company’s sale of
its Common Stock in a firm commitment underwritten public offering pursuant to a registration statement on Form S-1 or Form SB-2 under the Securities Act of 1933, as amended, resulting in net proceeds to the Company of at least $50,000,000 in the aggregate
and a pre-offering equity valuation of at least $250,000,000 (other than a registration statement relating either to the sale of securities to employees of the Company pursuant to a stock option, stock purchase or similar plan or a SEC Rule 145 transaction) or
(b) the consummation of a Liquidation Event, as that term is defined in the Company’s Articles of Incorporation (as amended from time to time).

15.

Manner of Voting. The voting of shares pursuant to this Agreement may be effected in person, by proxy, by written consent or in any other
manner permitted by applicable law.

16.

Amendments and Waivers. Any term hereof may be amended and the observance of any term hereof may be waived (either generally or in a
particular instance and either retroactively or prospectively) only with the written consent of (i) the Company, (ii) the holders of a majority of the then outstanding voting securities held by the Common Holders and (iii) the Required Holders. Notwithstanding
the foregoing, (a) the provisions of Section 3(a) may be amended and the observance of 

- 6 -

any term thereof may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the holders
of a majority of the then outstanding voting securities held by the Common Holders, (b) the provisions of Section 3(b) may be amended and the observance of any term thereof may be waived (either generally or in a particular instance and either retroactively or
prospectively) only with the written consent of IGC, (c) the provisions of Section 3(c) may be amended and the observance of any term thereof may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the
written consent of WCP, and (d) the provisions of Section 5 may be amended and the observance of any term thereof may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Required
Holders. Any amendment or waiver so effected by this Section 16 shall be binding upon all the Parties hereto.

17.

Stock Splits, Stock Dividends, etc. In the event of any issuance of shares of the Company’s voting securities hereafter to any of the
Parties hereto (including, without limitation, in connection with any stock split, stock dividend, recapitalization, reorganization or the like), such shares shall become subject to this Agreement and shall be endorsed with the legend set forth in Section 6.

18.

Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such
provision or the remaining provisions of this Agreement.

19.

Binding Effect. In addition to any restriction on transfer that may be imposed by any other agreement by which any Party hereto may be
bound, this Agreement shall be binding upon the Parties, their respective heirs, successors, transferees and assigns and to such additional individuals or entities that may become shareholders of the Company and that desire to become Parties hereto; provided
that for any such transfer to be deemed effective, the transferee shall have executed and delivered an Adoption Agreement substantially in the form attached hereto as Exhibit A. Upon the execution and delivery of an Adoption Agreement by a transferee
reasonably acceptable to the Company, such transferee shall be deemed to be a Party hereto as if such transferee’s signature appeared on the signature pages hereto. By its execution hereof or any Adoption Agreement, each of the Parties hereto appoints
the Company as its attorney-in-fact for the purpose of executing any Adoption Agreement which may be required to be delivered hereunder.

20.

Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard
to conflicts of law principles thereof.

21.

Entire Agreement. This Agreement is intended to be the sole agreement of the Parties as it relates to the subject matter hereof and
supersede all other agreements, including the Prior Agreement, of the Parties relating to the subject matter hereof. 

22.

Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

23.

Arbitration. Any controversy between the Parties hereto involving any claim arising out of or relating to the termination of this
Agreement, will be submitted to and be settled by final and binding arbitration in New York, New York, in accordance with the then current Commercial Arbitration Rules of the American Arbitration Association (the “AAA”), and judgment
upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. Such arbitration shall be conducted by three (3) arbitrators chosen by the Company, the Required Holders and the Common 

- 7 -

Holders, or failing such agreement, an arbitrator appointed by the AAA. There shall be limited discovery prior to the arbitration hearing as follows:
(a) exchange of witness lists and copies of documentary evidence and documents relating to or arising out of the issues to be arbitrated, (b) depositions of all party witnesses and (c) such other depositions as may be allowed by the arbitrators upon a
showing of good cause. Depositions shall be conducted in accordance with the New York Code of Civil Procedure, the arbitrator shall be required to provide in writing to the Parties the basis for the award or order of such arbitrator, and a court reporter
shall record all hearings, with such record constituting the official transcript of such proceedings.

- 8 -

    

IN WITNESS WHEREOF, the Parties have executed this Agreement effective as of the date first above written.

COMPANY:

GREENWAY MEDICAL TECHNOLOGIES, INC.

By:

______________________________

Name:

Title:

Address:

SERIES B INVESTORS:

WACHOVIA CAPITAL PARTNERS 2006, LLC

By:

______________________________

Name:

Title:

Address:

- 2 -

SERIES A INVESTORS:

INVESTOR GROWTH CAPITAL LIMITED

By:

______________________________

Name:

Title:

By:

______________________________

Name:

Title:

Address:

INVESTOR GROUP LP

By: Investor Group G.P. Limited

By:

______________________________

Name:

Title:

By:

______________________________

Name:

Title:

Address:

- 3 -

COMMON HOLDERS:

___________________________________________
 

By:

______________________________
 

Name:

______________________________
 

Title:

______________________________
 

Address:

______________________________

 

______________________________

By:

______________________________
 

Name:

______________________________
 

Title:

______________________________
 

Address:

______________________________

 

______________________________

- 4 -Exhibit 10.2

GREENWAY MEDICAL TECHNOLOGIES, INC.

2004 STOCK PLAN

ADOPTED ON JUNE 15, 2004

TABLE OF CONTENTS

		
	 

	Page No.

	 	 
	SECTION 1.  ESTABLISHMENT AND PURPOSE

	1

	 	 
	SECTION 2.  ADMINISTRATION

	1

	 	 
	     (a)  Committees of the Board of Directors

	1

	     (b)  Authority of the Board of Directors

	1

	 	 
	SECTION 3.  ELIGIBILITY

	1

	 	 
	     (a)  General Rule

	1

	     (b)  Ten-Percent Shareholders

	1

	 	 
	SECTION 4.  STOCK SUBJECT TO PLAN

	2

	 	 
	     (a)  Basic Limitation

	2

	     (b)  Additional Shares

	2

	 	 
	SECTION 5.  TERMS AND CONDITIONS OF AWARDS OR SALES

	2

	 	 
	     (a)  Stock Purchase Agreement

	2

	     (b)  Duration of Offers and Nontransferability of Rights

	2

	     (c)  Purchase Price

	2

	     (d)  Withholding Taxes

	2

	     (e)  Restrictions on Transfer of Shares

	2

	 	 
	SECTION 6.  TERMS AND CONDITIONS OF OPTIONS

	3

	 	 
	     (a)  Stock Option Agreement

	3

	     (b)  Number of Shares

	3

	     (c)  Exercise Price

	3

	     (d)  Exercisability

	3

	     (e)  Term

	3

	     (f)  Restrictions on Transfer of Shares

	3

	     (g)  Transferability of Options

	3

	     (h)  Withholding Taxes

	4

	     (i)  No Rights as a Shareholder

	4

	     (j)  Modification, Extension and Assumption of Options

	4

	 	 
	SECTION 7. PAYMENT FOR SHARES

	4

	 	 
	     (a)  General Rule

	4

	     (b)  Surrender of Stock

	4

	     (c)  Services Rendered

	4

	     (d)  Promissory Note

	4

	     (e)  Exercise/Sale

	5

i

		
	     (f)  Exercise/Pledge

	5

	 	 
	SECTION 8.  ADJUSTMENT OF SHARES

	5

	 	 
	     (a)  General

	5

	     (b)  Mergers and Consolidations

	5

	 	 
	SECTION 9.  SECURITIES LAWS REQUIREMENTS

	6

	 	 
	SECTION 10.  NO RETENTION RIGHTS

	7

	 	 
	SECTION 11.  DURATION AND AMENDMENTS

	7

	 	 
	     (a)  Term of the Plan

	7

	     (b)  Right to Amend or Terminate the Plan

	7

	     (c)  Effect of Amendment or Termination

	7

	 	 
	SECTION 12.  DEFINITIONS

	7

ii

GREENWAY MEDICAL TECHNOLOGIES, INC. 2004 STOCK PLAN

SECTION 1.

ESTABLISHMENT AND PURPOSE.

The purpose of the Plan is to offer selected persons an opportunity to acquire a proprietary interest in the success of the Company, or to increase
such interest, by purchasing Shares of the Company’s Stock. The Plan provides both for the direct award or sale of Shares and for the grant of Options to purchase Shares. Options granted under the Plan may include Nonstatutory Options as well as ISOs
intended to qualify under Section 422 of the Code.

Capitalized terms are defined in Section 12.

SECTION 2.

ADMINISTRATION.

(a)

Committees of the Board of Directors. The Plan may be administered by one or more Committees. Each Committee
shall consist of one or more members of the Board of Directors who have been appointed by the Board of Directors. Each Committee shall have such authority and be responsible for such functions as the Board of Directors has assigned to it. If no Committee
has been appointed, the entire Board of Directors shall administer the Plan. Any reference to the Board of Directors in the Plan shall be construed as a reference to the Committee (if any) to which the Board of Directors has assigned a particular function.

(b)

Authority of the Board of Directors. Subject to the provisions of the Plan, the Board of Directors shall have
full authority and discretion to take any actions it deems necessary or advisable for the administration of the Plan. All decisions, interpretations and other actions of the Board of Directors shall be final and binding on all Purchasers, all Optionees and
all persons deriving their rights from a Purchaser or Optionee.

SECTION 3.

ELIGIBILITY.

(a)

General Rule. Only Employees, Outside Directors and Consultants shall be eligible for the grant of Nonstatutory
Options or the direct award or sale of Shares. Only Employees shall be eligible for the grant of ISOs.

(b)

Ten-Percent Shareholders. A person who owns more than 10% of the total combined voting power of all classes of
outstanding stock of the Company, its Parent or any of its Subsidiaries shall not be eligible for the grant of an ISO unless (i) the Exercise Price is at least 110% of the Fair Market Value of a Share on the date of grant and (ii) such ISO by its
terms is not exercisable after the expiration of

five years from the date of grant. For purposes of this Subsection (b), in determining stock ownership, the attribution rules of Section 424(d) of the Code
shall be applied.

1

SECTION 4.

STOCK SUBJECT TO PLAN.

(a)

Basic Limitation. Not more than 304,273 Shares may be issued under the Plan (subject
to Subsection (b) below and Section 8). The number of Shares that are subject to Options or other rights outstanding at any time under the Plan shall not exceed the number of Shares that then remain available for issuance under the Plan. The Company,
during the term of the Plan, shall at all times reserve and keep available sufficient Shares to satisfy the requirements of the Plan. Shares offered under the Plan may be authorized but unissued Shares or treasury Shares.

(b)

Additional Shares. In the event that Shares previously issued under the Plan are
reacquired by the Company, such Shares shall be added to the number of Shares then available for issuance under the Plan. In the event that an outstanding Option or other right for any reason expires or is canceled, the Shares allocable to the unexercised
portion of such Option or other right shall be added to the number of Shares then available for issuance under the Plan.

SECTION 5.

TERMS AND CONDITIONS OF AWARDS OR SALES.

(a)

Stock Purchase Agreement. Each award or sale of Shares under the Plan (other than upon exercise of an Option)
shall be evidenced by a Stock Purchase Agreement between the Purchaser and the Company. Such award or sale shall be subject to all applicable terms and conditions of the Plan and may be subject to any other terms and conditions that are not inconsistent with
the Plan and that the Board of Directors deems appropriate for inclusion in a Stock Purchase Agreement. The provisions of the various Stock Purchase Agreements entered into under the Plan need not be identical.

(b)

Duration of Offers and Nontransferability of Rights. Any right to acquire Shares under the Plan (other than an
Option) shall automatically expire if not exercised by the Purchaser within 30 days after the grant of such right was communicated to the Purchaser by the Company. Such right shall not be transferable and shall be exercisable only by the Purchaser to whom
such right was granted.

(c)

Purchase Price. The Purchase Price of Shares to be offered under the Plan, if newly issued, shall not be less
than the par value of such Shares. Subject to the preceding sentence, the Board of Directors shall determine the Purchase Price at its sole discretion. The Purchase Price shall be payable in a form described in Section 7.

(d)

Withholding Taxes. As a condition to the purchase of Shares, the Purchaser shall make such arrangements as the
Board of Directors may require for the satisfaction of any federal, state, local or foreign withholding tax obligations that may arise in connection with such purchase.

(e)

Restrictions on Transfer of Shares. Any Shares awarded or sold under the Plan shall be subject to such special
forfeiture conditions, rights of repurchase, rights of first refusal and other transfer restrictions as the Board of Directors may determine. Such restrictions shall be set forth in the applicable Stock Purchase Agreement and shall apply in addition to any
restrictions that may apply to holders of Shares generally. A Stock Purchase Agreement may

2

 

provide for accelerated vesting in the event of the Purchaser’s death, disability or retirement or other events.

SECTION 6.

TERMS AND CONDITIONS OF OPTIONS.

(a)

Stock Option Agreement. Each grant of an Option under the Plan shall be evidenced by a Stock Option Agreement
between the Optionee and the Company. Such Option shall be subject to all applicable terms and conditions of the Plan and may be subject to any other terms and conditions that are not inconsistent with the Plan and that the Board of Directors deems appropriate
for inclusion in a Stock Option Agreement. The provisions of the various Stock Option Agreements entered into under the Plan need not be identical.

(b)

Number of Shares. Each Stock Option Agreement shall specify the number of Shares that are subject to the Option
and shall provide for the adjustment of such number in accordance with Section 8. The Stock Option Agreement shall also specify whether the Option is an ISO or a Nonstatutory Option.

(c)

Exercise Price. Each Stock Option Agreement shall specify the Exercise Price. The Exercise Price of an ISO
shall not be less than 100% of the Fair Market Value of a Share on the date of grant, and a higher percentage may be required by Section 3(b). The Exercise Price of a Nonstatutory Option to purchase newly issued Shares shall not be less than 30% of the
Fair Market Value of a Share on the date of grant. Subject to the preceding two sentences, the Exercise Price under an Option shall be determined by the Board of Directors at its sole discretion. The Exercise Price shall be payable
in a form described in Section 7.

(d)

Exercisability. Each Stock Option Agreement shall specify the date when all or any
installment of the Option is to become exercisable. No Option shall be exercisable unless the Optionee has delivered an executed copy of the Stock Option Agreement to the Company. The Board of Directors shall determine the exercisability provisions of any
Stock Option Agreement at its sole discretion. All of an Optionee’s Options shall become exercisable in full if Section 8(b)(iv) applies.

(e)

Term. The Stock Option Agreement shall specify the term
of the Option. The term shall not exceed 10 years from the date of grant,
and in the case of an ISO a shorter term may be required by Section 3(b). Subject to the preceding sentence, the Board of Directors at its sole discretion
shall determine when an Option is to expire. A Stock Option Agreement may provide for expiration prior to the end of its term in the event of the termination of the Optionee’s Service or death.

(f)

Restrictions on Transfer of Shares. Any Shares issued upon exercise of an Option
shall be subject to such special forfeiture conditions, rights of repurchase, rights of first refusal and other transfer restrictions as the Board of Directors may determine. Such restrictions shall be set forth in the applicable Stock Option Agreement and
shall apply in addition to any restrictions that may apply to holders of Shares generally.

(g)

Transferability of Options. An Option shall be transferable by the Optionee only
by (i) a beneficiary designation, (ii) a will or (iii) the laws of descent and

3

 

distribution, except as provided in the next sentence. If the applicable Stock Option Agreement so provides, a Nonstatutory Option shall also be
transferable by
gift or domestic relations order to a Family Member of the Optionee. An ISO may be exercised during the lifetime of the Optionee only by the Optionee or by the Optionee’s guardian or legal representative.

(h)

Withholding Taxes. As a condition to the exercise of an Option, the Optionee shall
make such arrangements as the Board of Directors may require for the satisfaction of any federal, state, local or foreign withholding tax obligations that may arise in connection with such exercise. The Optionee shall also make such arrangements as the Board
of Directors may require for the satisfaction of any federal, state, local or foreign withholding tax obligations that may arise in connection with the disposition of Shares acquired by exercising an Option.

(i)

No Rights as a Shareholder. An Optionee, or a transferee of an Optionee, shall have
no rights as a shareholder with respect to any Shares covered by the Optionee’s Option until such person becomes entitled to receive such Shares by filing a notice of exercise and paying the Exercise Price pursuant to the terms of such Option.

(j)

Modification, Extension and Assumption of Options. Within the limitations of the
Plan, the Board of Directors may modify, extend or assume outstanding Options or may accept the cancellation of outstanding Options (whether granted by the Company or another issuer) in return for the grant of new Options for the same or a different number
of Shares and at the same or a different Exercise Price. The foregoing notwithstanding, no modification of an Option shall, without the consent of the Optionee, impair the Optionee’s rights or increase the Optionee’s obligations under such Option.

SECTION 7.

PAYMENT FOR SHARES.

(a)

General Rule. The entire Purchase Price or Exercise Price of Shares issued under the Plan shall be payable
in cash or cash equivalents at the time when such Shares are purchased, except as otherwise provided in this Section 7.

(b)

Surrender of Stock. At the discretion of the Board of Directors, all or any part of the Exercise Price may
be paid by surrendering, or attesting to the ownership of, Shares that are already owned by the Optionee. Such Shares shall be surrendered to the Company in good form for transfer and shall be valued at their Fair Market Value on the date when the Option
is exercised. The Optionee shall not surrender, or attest to the ownership of, Shares in payment of the Exercise Price if such action would cause the Company to recognize compensation expense (or additional compensation expense) with respect to the Option
for financial reporting purposes.

(c)

Services Rendered. At the discretion of the Board of Directors, Shares may be
awarded under the Plan in consideration of services rendered to the Company, a Parent or a Subsidiary prior to the award.

(d)

Promissory Note. At the discretion of the Board of Directors, all or a portion of the Exercise Price or
Purchase Price (as the case may be) of Shares issued under the Plan may be paid with a full-recourse promissory note. However, the par value of the Shares, if 

4

 

newly issued, shall be paid in cash or cash equivalents. The Shares shall be pledged as security
for payment of the principal amount of the promissory note and interest thereon. The interest rate payable under the terms of the promissory note shall not be less than the minimum rate (if any) required to avoid (i) the imputation of additional interest
under the Code and (ii) variable accounting under the applicable guidelines issued by the Financial Accounting Standards Board. Subject to the foregoing, the Board of Directors (at its sole discretion) shall specify the term, interest rate, amortization
requirements (if any) and other provisions of such note.

(e)

Exercise/Sale. To the extent that a Stock Option Agreement so provides, and if Stock is publicly traded,
payment may be made all or in part by the delivery (on a form prescribed by the Company) of an irrevocable direction to a securities broker approved by the Company to sell Shares and to deliver all or part of the sales proceeds to the Company in payment
of all or part of the Exercise Price and any withholding taxes.

(f)

Exercise/Pledge. To the extent that a Stock Option Agreement so provides, and if Stock is publicly traded,
payment may be made all or in part by the delivery (on a form prescribed by the Company) of an irrevocable direction to pledge Shares to a securities broker or lender approved by the Company, as security for a loan, and to deliver all or part of the loan
proceeds to the Company in payment of all or part of the Exercise Price and any withholding taxes.

SECTION 8.

ADJUSTMENT OF SHARES.

(a)

General. In the event of a subdivision of the outstanding Stock, a declaration of
a dividend payable in Shares or a combination or consolidation of the outstanding Stock into a lesser number of Shares, corresponding adjustments shall automatically be made in each of (i) the number of Shares available for future grants under
Section 4, (ii) the number of Shares covered by each outstanding Option and (iii) the Exercise Price under each outstanding Option. In the event of a declaration of an extraordinary dividend payable in a form other than Shares in an
amount that has a material effect on the Fair Market Value of the Stock, a recapitalization, a spin-off, a reclassification or a similar occurrence, the Board of Directors at its sole discretion may make appropriate adjustments in one or more of
(i) the number of Shares available for future grants under Section 4, (ii) the number of Shares covered by each outstanding Option or (iii) the Exercise Price under each outstanding Option.

(b)

Mergers and Consolidations. In the event that the Company is a party to a merger
or consolidation, all outstanding Options shall be subject to the agreement of merger or consolidation. Such agreement shall provide for one or more of the following:

            (i)   The continuation of such outstanding Options
by the Company (if the Company is
the surviving corporation).

            (ii)  The assumption of such outstanding Options by the surviving corporation or its parent in a manner that complies
with Section 424(a) of the Code (whether or not such Options are ISOs).

5

            (iii)  The substitution by
the surviving corporation or its parent of new options for such outstanding Options in a
manner that complies with Section 424(a) of the Code (whether or not such Options are ISOs).

            (iv)  Full exercisability
of such outstanding Options and full vesting of the Shares subject to such Options,
followed by the cancellation of such Options. The full exercisability of such Options and full vesting of the Shares subject to such Options may be contingent on the closing of such merger or consolidation. The Optionees shall be able to exercise such
Options during a period of not less than five full business days preceding the closing date of such merger or consolidation, unless (A) a shorter period is required to permit a timely closing of such merger or consolidation and (B) such shorter
period still offers the Optionees a reasonable opportunity to exercise such Options. Any exercise of such Options during such period may be contingent on the closing of such merger or consolidation.

            (v)  The cancellation of such outstanding Options and a payment to the Optionees equal to the excess of
(A) the Fair Market Value of the Shares subject to such Options (whether or not such Options are then exercisable or such Shares are then vested) as of the closing date of such merger or

consolidation over (B) their Exercise Price. Such payment shall be made in the form of cash, cash equivalents, or
securities of the surviving corporation or its parent with a Fair Market Value equal to the required amount. Such payment may be made in installments and may be deferred until the date or dates when such Options would have become exercisable or such
Shares would have vested. Such payment may be subject to vesting based on the Optionee’s continuing Service, provided that the vesting schedule shall not be less favorable to the Optionees than the schedule under which such Options would have
become exercisable or such Shares would have vested. If the Exercise Price of the Shares subject to such Options exceeds the Fair Market Value of such Shares, then such Options may be cancelled without making a payment to the Optionees. For purposes
of this Paragraph (v), the Fair Market Value of any security shall be determined without regard to any vesting conditions that may apply to such security.

SECTION 9.

SECURITIES LAW REQUIREMENTS.

Shares shall not be issued under the Plan unless the issuance and delivery of such Shares comply with (or are exempt from) all applicable
requirements of law, including (without limitation) the Securities Act of 1933, as amended, the rules and regulations promulgated thereunder, state securities laws and regulations, and the regulations of any stock exchange or other securities market
on which the Company’s securities may then be traded.

6

SECTION 10.

  NO RETENTION RIGHTS.

Nothing in the Plan or in any right or Option granted under the Plan shall confer upon the Purchaser or Optionee any right to continue in
Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company (or any Parent or Subsidiary employing or retaining the Purchaser or Optionee) or of the Purchaser or Optionee, which rights are
hereby expressly reserved by each, to terminate his or her Service at any time and for any reason, with or without cause.

SECTION 11.

  DURATION AND AMENDMENTS.

(a)

Term of the Plan. The Plan, as set forth herein, shall become effective on the
date of its adoption by the Board of Directors, subject to the approval of the Company’s shareholders. If the shareholders fail to approve the Plan within 12 months after its adoption by the Board of Directors, then any grants, exercises or sales
that have already occurred under the Plan shall be rescinded and no additional grants, exercises or sales shall thereafter be made under the Plan. The Plan shall terminate automatically ten years after the later of (i) its adoption by the Board of
Directors or (ii) the most recent increase in the number of Shares reserved under Section 4 that was approved by the Company’s shareholders. The Plan may be terminated on any earlier date pursuant to Subsection (b) below.

(b)

Right to Amend or Terminate the Plan. The Board of Directors may amend, suspend or terminate the Plan at any time and for any reason;
provided, however, that any amendment of the Plan shall be subject to the approval of the Company’s shareholders if it (i) increases the number of Shares available for issuance under the Plan (except as provided in Section 8) or
(ii) materially changes the class of persons who are eligible for the grant of ISOs. Shareholder approval shall not be required for any other amendment of the Plan. If the shareholders fail to approve an increase in the number of Shares reserved
under Section 4 within 12 months after its adoption by the Board of Directors, then any grants, exercises or sales that have already occurred in reliance on such increase shall be rescinded and no additional grants, exercises or sales shall thereafter
be made in reliance on such increase.

(c)

Effect of Amendment or Termination. No Shares shall be issued or sold under the Plan after the termination thereof, except upon exercise
of an Option granted prior to such termination. The termination of the Plan, or any amendment thereof, shall not affect any Share previously issued or any Option previously granted under the Plan.

SECTION 12.

  DEFINITIONS.

(a)

“Board of Directors” shall mean the Board of Directors of the Company, as constituted from time to time.

(b)

“Code” shall mean the Internal Revenue Code of 1986, as amended.

(c)

“Committee” shall mean a committee of the Board of Directors, as described in Section 2(a).

7

(d)

“Company” shall mean Greenway Medical Technologies, Inc., a Georgia corporation.

(e)

“Consultant” shall mean a person who performs bona fide services for the Company, a Parent or a Subsidiary as a consultant or
advisor, excluding Employees and Outside Directors.

(f)

“Employee” shall mean any individual who is a common-law employee of the Company, a Parent or a Subsidiary.

(g)

“Exercise Price” shall mean the amount for which one Share may be purchased upon exercise of an Option, as specified by the
Board of Directors in the applicable Stock Option Agreement.

(h)

“Fair Market Value” shall mean the fair market value of a Share, as determined by the Board of Directors in good faith. Such
determination shall be conclusive and binding on all persons.

(i)

“Family Member” shall mean (i) any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse,
sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law, including adoptive relationships, (ii) any person sharing the Optionee’s household (other than a tenant or employee), (iii) a trust in
which persons described in Clause (i) or (ii) have more than 50% of the beneficial interest, (iv) a foundation in which persons described in Clause (i) or (ii) or the Optionee control the management of assets and (v) any other entity in which persons
described in Clause (i) or (ii) or the Optionee own more than 50% of the voting interests.

(j)

“ISO” shall mean an employee incentive stock option described in Section 422(b) of the Code.

(k)

“Nonstatutory Option” shall mean a stock option not described in Sections 422(b) or 423(b) of the Code.

(l)

“Option” shall mean an ISO or Nonstatutory Option granted under the Plan and entitling the holder to purchase Shares.

(m)

“Optionee” shall mean a person who holds an Option.

(n)

“Outside Director” shall mean a member of the Board of Directors who is not an Employee.

(o)

“Parent” shall mean any corporation (other than the Company) in an unbroken chain of corporations ending with the Company, if
each of the corporations other than the Company owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. A corporation that attains the status of a Parent on a date after the
adoption of the Plan shall be considered a Parent commencing as of such date.

8

(p)

“Plan” shall mean this Greenway Medical Technologies, Inc. 2004 Stock Plan. 

(q)

“Purchase Price” shall mean the consideration for which one Share may be acquired under the Plan (other than upon exercise of an
Option), as specified by the Board of Directors.

(r)

“Purchaser” shall mean a person to whom the Board of Directors has offered the right to acquire Shares under the Plan (other
than upon exercise of an Option).

(s)

“Service” shall mean service as an Employee, Outside Director or Consultant.

(t)

“Share” shall mean one share of Stock, as adjusted in accordance with Section 8 (if applicable).

(u)

“Stock” shall mean the $1.00 par value per share common stock of the Company.

(v)

“Stock Option Agreement” shall mean the agreement between the Company and an Optionee that contains the terms, conditions and
restrictions pertaining to the Optionee’s Option.

(w)

“Stock Purchase Agreement” shall mean the agreement between the Company and a Purchaser who acquires Shares under the Plan that
contains the terms, conditions and restrictions pertaining to the acquisition of such Shares.

(x)

“Subsidiary” shall mean any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company,
if each of the corporations other than the last corporation in the unbroken chain owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corpora­tions in such chain. A corporation that attains the
status of a Subsidiary on a date after the adoption of the Plan shall be considered a Sub­sidiary commencing as of such date.

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}]]